BRIEF-Exelixis' Cabozantinib meets key goal in late-stage trial
October 16, 2017 at 07:19 AM EDT
* Exelixis' phase 3 celestial trial of Cabozantinib meets primary endpoint of overall survival in patients with advanced hepatocellular carcinoma